# Full Operating Cycle Rerun

Date: 2026-05-31
Policy version: v1.1
Request type: full_operating_cycle and monthly_decision

## Scope

This rerun executed the repository operating cycle after the user requested a literal full run and concrete investment decision. It covered account-state reconstruction, market refresh, universe discovery, agentic discovery, freshness and filing review, AI-cycle and market-regime review, watchlist-cycle review, allocation, meta-self-improvement, data cleanup, and validation.

No trades were executed. Broker-confirmed account records were not changed.

## Account State

Confirmed broker facts remain:

- Confirmed cash: USD 888.00.
- Settled cash: USD 888.00.
- Buying power: USD 888.00.
- Broker-confirmed positions: none.
- Confirmed liquidity reserve: none.

## Deterministic Commands

`npm run refresh:market` refreshed tradable watchlist history and metrics through the 2026-05-29 U.S. market close. Since the run occurred on Sunday 2026-05-31, no newer regular-session close was available.

`npm run discover:universe -- --dry-run` and the JSON audit scan refreshed deterministic raw leads. The scanner remains keyword scaffolding, not a buy list.

`npm run build:evidence-packet -- --as-of 2026-05-31 --output research/discovery/runs/2026-05-31-subagent-evidence-packet.yml` rebuilt the bounded packet for advisory reviewers.

## Discovery Result

No discovery lane was added, split, promoted, demoted, merged, or retired.

FLY remains incubating research-only after completed readiness. It is a real same-lane space infrastructure candidate, but valuation, losses, runway, selling-holder risk, dilution risk, and short public history keep it below RKLB and ASTS today.

NNE is a future advanced-nuclear readiness backlog item before any nuclear/power allocation review. It does not block today's space and direct-to-device allocation.

## Freshness Result

RKLB and ASTS staged buys are not blocked by active-name freshness:

- RKLB's 2026-05-29 Form 144 director proposed sale and Form SD were recorded as reviewed, non-blocking events.
- ASTS's 2026-05-27 Form 144 officer proposed sale was recorded as reviewed, non-blocking.

The broader full-cycle review found and resolved missing watch/research-only freshness items:

- IREN USD 3.0 billion convertible notes.
- OKLO USD 1.0 billion ATM equity program.
- CRCL USD 221,999,998 token purchase agreement Form D.
- RDW USD 350 million ATM and Series A preferred conversion.
- IONQ SkyWater transaction material.
- NBIS MagicByte/Eigen AI Labs acquisition.

These reviews reinforce no-buy or no-promotion conclusions for those names; they do not create a superior current allocation candidate.

## AI-Cycle And Market-Regime Result

AI infrastructure demand remains strong. Hyperscaler capex, AI networking, and data-center power constraints strengthen the AI interconnect and power/cooling lanes. The same evidence does not make CRDO, ALAB, or VRT a current first-cash buy because valuation, concentration, and lower extreme-upside asymmetry still matter.

The Federal Reserve financial-stability backdrop and financing-sensitive watchlist events support smaller staged sizing, strict limits, and cash as an active alternative.

## Allocation Result

The resolved decision is smaller than the old historical 4 RKLB and 2 ASTS plan:

| Side | Symbol | Quantity | Limit price | Max cash use |
| --- | --- | ---: | ---: | ---: |
| Buy | RKLB | 3 | USD 143.50 | USD 430.50 |
| Buy | ASTS | 1 | USD 113.50 | USD 113.50 |

Total maximum use: USD 544.00 before fees.

Estimated retained cash: USD 344.00 before fees.

The order is valid only for the next U.S. regular session, expected 2026-06-01, and only if broker preview and live quotes preserve the limits.

## Meta-Self-Improvement

The main lesson is that full-cycle freshness cannot stop at buy-zone names. Watch and research-only names can contain financing or transaction events that do not change today's buy list but still matter for repository readiness and future promotion gates.

No new process rule was required because the existing strengthened readiness and freshness rules already caught the issue. The durable fix was to complete the reviews and update the research state.

## Validation

Validation to run after this rerun:

- `npm run check:data`
- `npm run test:discovery-gates`
- `npm run test:promotion-gates`
- `npm run test:watchlist-cycle-gates`
- `npm run verify`
